COUTINHO ELSIMAR METZKER
No ORCID on file
· 82 papers in corpus
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.
1992
The invention concerns the use of 16-methylene-17 alpha -acetoxy-19-nor-progesterone for the manufacture of a pharmaceutical composition for the treatment of endometriosis and other estrogen-dependent conditions.